In the small cap segment Ablynx is one of the outperformers. Over the past 12 months the small cap is an impressive 203 percent higher. The European glamour stocks are 27 percent higher. Investors pay now -63 times the CAPE-ratio per share. The average European glamour stocks are traded at 17.
Over the current book year the total revenue will be 66,59 million euros (consensus estimates). This is rather significant lower than 2016's revenue of 85,19 million euros.
The analysts expect for 2018 a net loss of 60 million euros. For this year most of the analysts expect a loss per share of 89 cent. Based on this the price/earnings-ratio is -40,27.
Analysts don't expect the company to pay a dividend.The average dividend yield of the biotech companies is a low 0,06 percent.
Based on the current number of shares Ablynx 's market capitalization equals 1,96 billion euros.At 13.13 the stock trades 5,75 percent higher at 35,84 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.